On Monday, April 6, GW Pharmaceuticals revealed that the company had received notice from the U.S. Drug Enforcement Administration (“DEA”) stating that its drug Epidiolex was no longer subject to the requirements of the Controlled Substances Act (“CSA”). In a company release announcing the agency … Read more about DEA Removes CBD from Controlled Substances Act
Epidiolex Now Available Across US
Epidiolex, the first FDA-approved cannabis-based medication, is now available via prescription in all US states. Produced by GW Pharmaceuticals, the drug received approval by the US Food and Drug Administration (FDA) in June, followed by a narrow rescheduling by the US Drug … Read more about Epidiolex Now Available Across US
DEA Reschedules CBD-Based Epidiolex
The Drug Enforcement Administration (DEA) has rescheduled the cannabidiol (CBD) based drug Epidolex, but limited the rescheduling to exclude all CBD products. Epidiolex will be scheduled at Schedule 5, the lowest level of drug scheduling under the Controlled Substances Act (CSA). Epidiolex, … Read more about DEA Reschedules CBD-Based Epidiolex